Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients

Haematologica. 2020 Apr;105(4):e190-e193. doi: 10.3324/haematol.2019.226696. Epub 2019 Aug 8.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Antigens, CD20
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Humans
  • Killer Cells, Natural
  • Leukocytes, Mononuclear*
  • Lymphoma* / drug therapy
  • Rituximab


  • Antigens, CD20
  • Rituximab